COVID-19 Vaccination Approach Survey
Members of the American Academy of Allergy, Asthma & Immunology (AAAAI) based in the United States were recently surveyed regarding their approach to patients with possible allergy to COVID-19 mRNA vaccines. The survey was completed by 142 individuals (18% response rate).
Here is a summary of the results:
- 92% were not administering the vaccine in their office, while 8% were administering in their office
- 82% had evaluated patients to clear them for their first dose of the Pfizer or Moderna vaccine
- In the evaluation of such patients, 50% did no testing, 49% did skin testing to polyethylene glycol, and 33% did skin testing to polysorbate
- 55% had evaluated patients with reactions to their first dose of the Pfizer or Moderna vaccine
- Among those who had not evaluated such patients, 85% had not received these referrals
- Among patients evaluated for a reaction to their first dose, approaches by respondents were as follows:
- 47% did no testing, 47% skin tested to polytheylene glycol, 36% skin tested to polysorbate, and 32% obtained a baseline tryptase
- 69% used telehealth (especially telephone visits and video visits) in the evaluation
- In patients with an immediate reaction to their first dose, a second dose was recommended by
- 11%, whether or not the reaction was likely anaphylaxis
- 40%, only in patients whose reaction was possibly allergic but not anaphylaxis
- 40%, only in patients whose symptoms were not consistent with allergy
- 9%, in no patients with prior reactions
- In administering the second dose to individuals with reactions to their first dose
- 61% used antihistamine pretreatment, 28% used no pretreatment, and 11% used other pretreatment
- 84% administered the full dose, 13% a two-dose challenge, and 3% more than two doses
- 74% recommended a 30 minute waiting period after the injection, and 23% recommended a 60 minute waiting period
Clinician Wellness During COVID-19: Maintaining Personal Health While Navigating Unexpected Challenges in Extraordinary Times
COVID-19: Pandemic Contingency Planning for Allergy and Immunology Clinic
Follow @JACIInPractice on Twitter.
Special Edition Virtual Journal Clubs
The JACI: In Practice and the New Allergist/Immunologist Assembly (NAIA) provide special edition webinars to provide practical guidance to allergy/immunology clinicians during the COVID-19 pandemic.
Earn CME credit for these webinars!
Watch the recorded webinar discussing the JACI: In Practice article "A Phased Approach to Resuming Suspended Allergy/Immunology Clinical Services."
Watch the recorded webinar discussing the JACI: In Practice article, "AAAAI Work Group Report: COVID-19: Unmasking Telemedicine."
Watch the recorded webinar discussing two JACI: In Practice articles, "COVID-19: Pandemic Contingency Planning for the Allergy and Immunology Clinic" and "Telemedicine in the Era of COVID-19."
JACI: In Practice offers expedited reviews for COVID-19 related articles that are relevant to the field of clinical allergy/immunology and deemed by the editors to be potentially valuable to our readers. Simply submit your manuscript or send a proposal to [email protected].
If you are working remotely during the pandemic, we recommend reading this article by our Managing Editor, Dawn Angel.
AAAAI Resources for A/I Clinicians during the COVID-19 Pandemic